期刊
INFLAMMATORY BOWEL DISEASES
卷 26, 期 4, 页码 515-523出版社
OXFORD UNIV PRESS INC
DOI: 10.1093/ibd/izz193
关键词
end points; clinical trials; ulcerative colitis; Crohn's disease; maintenance therapy
资金
- NIDDK [K23DK117058]
- American College of Gastroenterology Junior Faculty Development Award
- Crohn's and Colitis Foundation Career Development Award [404614]
- Pfizer
- AbbVie
- AMAG Pharmaceuticals
- Takeda
- Prometheus, Polymedco
- Abbvie
- Robarts Clinical Trials, Inc.
- Robarts Clinical Trials Inc.
- Millennium Pharmaceuticals
- Tillotts Pharma
- Novartis Pharmaceuticals
- Elan/Biogen
- UCB Pharma
- Bristol-Myers Squibb
- Genentech
- ActoGenix
- Wyeth Pharmaceuticals
- Unity Pharmaceuticals, Albireo Pharma
- GiCare Pharma
- Sigmoid Pharma
- UCB
- JJ/Janssen
- Atlantic Healthcare Limited
- Celgene/Receptos
- Allergan
- Arena Pharmaceuticals
- BeiGene
- Conatus
- Kyowa Kirin Pharmaceutical Research
- Lilly
- Otsuka
- Prizer, Precision IBD, Progenity
- Shire
- Sigmoid Biotechnologies, Sterna Biologicals
- Progenity
- John and Susan McDonald Endowed IBD Chair at Western University
- Eli Lilly
- Pendopharm
- Robarts Clinical Trials, Topivert
Background: We summarized the protocol-specified corticosteroid tapering regimens in clinical trials of moderate-severe ulcerative colitis (UC) and Crohn's disease (CD) and calculated differences in rates of clinical remission vs corticosteroid-free clinical remission (CSF-CR). Methods: Through a systematic literature review through February 28, 2019, we identified 16 randomized controlled trials (RCTs) of biologics or small molecules in patients with moderate-severe UC or CD who reported CSF-CR as an outcome. We estimated the relative risk and 95% confidence interval of achieving CSF-CR vs overall clinical remission in patients treated with active intervention or placebo through random-effects meta-analysis. Results: Across trials of UC (11 trials) and CD (5 trials), a median of 53% and 49% of participants were on corticosteroids at the time of trial entry, respectively. Participants were allowed to enter trials at a median corticosteroid dose (range) of 35 (20-40) mg/d. Doses were kept stable for a median (range) of 8 (5-10) weeks during induction therapy, after which a mandatory and structured taper was implemented, albeit with the investigators' discretion depending on clinical status. Pooled rates of CSF-CR in patients with UC and CD treated with placebo were 9.7% and 19.1%, respectively. In UC and CD trials, the rate of CSF-CR was 24% and 18% lower than the rate of overall clinical remission, respectively. Conclusions: Protocol-specified corticosteroid tapering regimens vary across trials. These findings will help to inform the design and interpretation of future clinical trials and highlight the need for standardization.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据